OBJECTIVE: The objective of our study was to quantify the arteriogenic potency of Monocyte Chemoattractant Protein-1 (MCP-1) under hyperlipidemic conditions. Additionally, we aimed to determine the effects of locally applied MCP-1 on systemic serum lipid levels as well as on atherosclerosis. METHODS: A total of sixty-four Watanabe rabbits was treated with either low dose MCP-1 (1 microg/kg/week), high dose MCP-1 (3.3 microg/kg/week) or PBS as a control substance. Substances were applied directly into the collateral circulation via an osmotic minipump with the catheter placed in the proximal stump of the ligated femoral artery. Either 1 week or 6 months after initiation of the treatment X-ray angiography was performed as well as measurements of collateral conductance using fluorescent microspheres. The extent of atherosclerosis was quantified in whole aortas using Sudan IV staining. RESULTS: One week after ligation of the femoral artery a significant increase in collateral conductance was observed in animals treated with high dose MCP-1 (control: 2.2+/-0.8 ml/min/100 mmHg vs. MCP-1 high dose: 8.9+/-2.0 ml/min/100 mmHg, P<0.05). Six months after femoral artery ligation no differences were found between the treated and the control group (PBS; 44.9+/-11.6 ml/min/100 mmHg, MCP-1; 47.8+/-11.5 ml/min/100 mmHg, P=NS). No influence was found on serum lipids or on the development of atherosclerosis in the present model. CONCLUSION: MCP-1 accelerates arteriogenesis upon femoral artery ligation under hyperlipidemic conditions. Six months after treatment these pro-arteriogenic effects of MCP-1 can no longer be observed. The present data do not show an effect of local MCP-1 treatment on serum lipids or on atherosclerosis. It should be noted however that a high standard deviation was observed for the data on atherosclerotic surface area, necessitating additional experiments in a different model of atherosclerosis.
OBJECTIVE: The objective of our study was to quantify the arteriogenic potency of Monocyte Chemoattractant Protein-1 (MCP-1) under hyperlipidemic conditions. Additionally, we aimed to determine the effects of locally applied MCP-1 on systemic serum lipid levels as well as on atherosclerosis. METHODS: A total of sixty-four Watanabe rabbits was treated with either low dose MCP-1 (1 microg/kg/week), high dose MCP-1 (3.3 microg/kg/week) or PBS as a control substance. Substances were applied directly into the collateral circulation via an osmotic minipump with the catheter placed in the proximal stump of the ligated femoral artery. Either 1 week or 6 months after initiation of the treatment X-ray angiography was performed as well as measurements of collateral conductance using fluorescent microspheres. The extent of atherosclerosis was quantified in whole aortas using Sudan IV staining. RESULTS: One week after ligation of the femoral artery a significant increase in collateral conductance was observed in animals treated with high dose MCP-1 (control: 2.2+/-0.8 ml/min/100 mmHg vs. MCP-1 high dose: 8.9+/-2.0 ml/min/100 mmHg, P<0.05). Six months after femoral artery ligation no differences were found between the treated and the control group (PBS; 44.9+/-11.6 ml/min/100 mmHg, MCP-1; 47.8+/-11.5 ml/min/100 mmHg, P=NS). No influence was found on serum lipids or on the development of atherosclerosis in the present model. CONCLUSION:MCP-1 accelerates arteriogenesis upon femoral artery ligation under hyperlipidemic conditions. Six months after treatment these pro-arteriogenic effects of MCP-1 can no longer be observed. The present data do not show an effect of local MCP-1 treatment on serum lipids or on atherosclerosis. It should be noted however that a high standard deviation was observed for the data on atherosclerotic surface area, necessitating additional experiments in a different model of atherosclerosis.
Authors: Timur R Nasibullin; Yanina R Timasheva; Regina I Sadikova; Ilsiyar A Tuktarova; Vera V Erdman; Irina E Nikolaeva; Jan Sabo; Peter Kruzliak; Olga E Mustafina Journal: Mol Biol Rep Date: 2015-12-12 Impact factor: 2.316
Authors: Brian L Hoh; Koji Hosaka; Daniel P Downes; Kamil W Nowicki; Cristina E Fernandez; Christopher D Batich; Edward W Scott Journal: Circulation Date: 2011-10-17 Impact factor: 29.690
Authors: Steven M Jay; Benjamin R Shepherd; Jillian W Andrejecsk; Themis R Kyriakides; Jordan S Pober; W Mark Saltzman Journal: Biomaterials Date: 2010-01-27 Impact factor: 12.479
Authors: Yagai Yang; Gale Tang; Jinglian Yan; Brian Park; Ari Hoffman; Guodong Tie; Rong Wang; Louis M Messina Journal: J Vasc Surg Date: 2008-12 Impact factor: 4.268
Authors: Caroline Gray; Ian M Packham; François Wurmser; Nicholas C Eastley; Paul G Hellewell; Philip W Ingham; David C Crossman; Timothy J A Chico Journal: Arterioscler Thromb Vasc Biol Date: 2007-07-26 Impact factor: 8.311
Authors: Wilson Ranu Ramirez Nunez; Michiko Regina Ozaki; Adriana Mendes Vinagre; Edgard Ferro Collares; Eros Antonio de Almeida Journal: Arq Bras Cardiol Date: 2014-12-09 Impact factor: 2.000